151 related articles for article (PubMed ID: 34651428)
1. Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma.
Wang X; Shirazi F; Yan W; Liu X; Wang H; Orlowski RZ; Wang H
J Cell Mol Med; 2021 Nov; 25(21):10164-10174. PubMed ID: 34651428
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.
Zhang L; Pham LV; Newberry KJ; Ou Z; Liang R; Qian J; Sun L; Blonska M; You Y; Yang J; Lin X; Rollo A; Tamayo AT; Lee J; Ford RJ; Zhao X; Kwak LW; Yi Q; Wang M
Mol Cancer Ther; 2013 Nov; 12(11):2494-504. PubMed ID: 23990113
[TBL] [Abstract][Full Text] [Related]
3. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Attkisson E; Dent P; Fisher RI; Friedberg JW; Grant S
Mol Cancer Ther; 2011 Sep; 10(9):1686-97. PubMed ID: 21750224
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis.
Zhang YL; Guang MH; Zhuo HQ; Min XH; Yao Q; Gu AQ; Wu SH; Zhang DB; Lu JY; Chen Y; Chen YH; Zhang KJ
Acta Haematol; 2017; 137(2):106-112. PubMed ID: 28208145
[TBL] [Abstract][Full Text] [Related]
6. MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met.
Higuchi T; Orita T; Katsuya K; Yamasaki Y; Akiyama K; Li H; Yamamoto T; Saito Y; Nakamura M
Mol Cell Biol; 2004 Sep; 24(17):7456-68. PubMed ID: 15314156
[TBL] [Abstract][Full Text] [Related]
7. Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways.
Lei L; Zhang Y; Jian Q; Lei L; Lv N; Williamson RA; Chen P; Zhang D; Hu J
Exp Physiol; 2021 Feb; 106(2):438-449. PubMed ID: 33336554
[TBL] [Abstract][Full Text] [Related]
8. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
[TBL] [Abstract][Full Text] [Related]
11. MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.
Wang X; Shi Y; Shi H; Liu X; Liao A; Liu Z; Orlowski RZ; Zhang R; Wang H
J Exp Clin Cancer Res; 2024 Mar; 43(1):68. PubMed ID: 38439082
[TBL] [Abstract][Full Text] [Related]
12. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
[TBL] [Abstract][Full Text] [Related]
13. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Dasmahapatra G; Patel H; Friedberg J; Quayle SN; Jones SS; Grant S
Mol Cancer Ther; 2014 Dec; 13(12):2886-97. PubMed ID: 25239935
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Pérez-Galán P; Mora-Jensen H; Weniger MA; Shaffer AL; Rizzatti EG; Chapman CM; Mo CC; Stennett LS; Rader C; Liu P; Raghavachari N; Stetler-Stevenson M; Yuan C; Pittaluga S; Maric I; Dunleavy KM; Wilson WH; Staudt LM; Wiestner A
Blood; 2011 Jan; 117(2):542-52. PubMed ID: 20956803
[TBL] [Abstract][Full Text] [Related]
16. A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
Ben Younes K; Body S; Costé É; Viailly PJ; Miloudi H; Coudre C; Jardin F; Ben Aissa-Fennira F; Sola B
BMC Cancer; 2017 Aug; 17(1):538. PubMed ID: 28797244
[TBL] [Abstract][Full Text] [Related]
17. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
Chen ST; Kuo TC; Liao YY; Lin MC; Tien YW; Huang MC
Oncogene; 2018 Nov; 37(46):6041-6053. PubMed ID: 29993037
[TBL] [Abstract][Full Text] [Related]
18. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
[TBL] [Abstract][Full Text] [Related]
19. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
Zhang X; Schulz R; Edmunds S; Krüger E; Markert E; Gaedcke J; Cormet-Boyaka E; Ghadimi M; Beissbarth T; Levine AJ; Moll UM; Dobbelstein M
Mol Cell; 2015 Jul; 59(2):243-57. PubMed ID: 26145175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
